Compare BMHL & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMHL | CSBR |
|---|---|---|
| Founded | 2016 | 1985 |
| Country | Hong Kong | United States |
| Employees | 9 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.8M | 81.0M |
| IPO Year | N/A | 2015 |
| Metric | BMHL | CSBR |
|---|---|---|
| Price | $5.75 | $6.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 17.8K | 4.8K |
| Earning Date | 06-13-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 161.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,900,000.00 |
| Revenue This Year | N/A | $4.84 |
| Revenue Next Year | N/A | $11.51 |
| P/E Ratio | $66.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.72 | $5.50 |
| 52 Week High | $6.35 | $9.63 |
| Indicator | BMHL | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 69.23 | 50.30 |
| Support Level | $3.24 | $5.77 |
| Resistance Level | $6.35 | $6.31 |
| Average True Range (ATR) | 0.48 | 0.39 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 79.49 | 38.57 |
Bluemount Holdings Ltd through its operating subsidiaries, it is a Hong Kong-based consulting and advisory and financial services provider, as well as trader of commodities such as luxury timepieces. The financial services includes underwriting and placing services, securities dealing and brokerage services, and asset management services. It provides comprehensive consulting and advisory services on business development strategies to its diverse clientele. Generally, the company provides consulting and advisory business for the following segments: Corporate Finance; and Strategic Communications.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.